Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Ophthalmology Therapeutics Market in Asia-Pacific – Introduction 9
2.1 Dry Eye Syndrome 9
2.1.1 Classification 9
2.1.2 Symptoms 9
2.1.3 Etiology 9
2.1.4 Pathophysiology 10
2.1.5 Diagnosis 11
2.1.6 Epidemiology 12
2.1.7 Prognosis 13
2.1.8 Treatment Options 13
2.2 Glaucoma 14
2.2.1 Classification 14
2.2.2 Symptoms 15
2.2.3 Etiology 15
2.2.4 Pathophysiology 16
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 18
2.2.8 Treatment Options 19
3 Ophthalmology Therapeutics Market in Asia-Pacific – Marketed Products (Global) 20
3.1 Dry Eye Syndrome 20
3.2 Glaucoma 20
3.3 Key Marketed Products 21
3.3.1 Restasis 21
3.3.2 Systane 22
3.3.3 Diquas 23
3.3.4 Mucosta 24
3.3.5 Hyalein 25
3.3.6 Lumigan 26
3.3.7 Alphagan/Alphagan P 27
4 Ophthalmology Therapeutics Market in Asia-Pacific – Pipeline Analysis 28
4.1 Dry Eye Syndrome Pipeline 28
4.1.1 Overall Pipeline 28
4.1.2 Pipeline Analysis by Molecule Type 30
4.1.3 Pipeline Analysis by Mechanism of Action 31
4.2 Glaucoma Pipeline 33
4.2.1 Overall Pipeline 33
4.2.2 Pipeline Analysis by Molecule Type 34
4.2.3 Pipeline Analysis by Mechanism of Action 35
4.3 Promising Drug Candidates in the Pipeline 37
4.3.1 CF-101 37
4.3.2 MIM-D3 37
4.3.3 SAR-1118 37
4.3.4 DE-111 38
5 Ophthalmology Therapeutics Market in Asia-Pacific – Market Forecast to 2018 39
5.1 APAC Market 39
5.1.1 Treatment Usage Patterns 39
5.1.2 Annual Cost of Therapy 39
5.1.3 Market Size 39
5.2 India 41
5.2.1 Treatment Usage Patterns 41
5.2.2 Annual Cost of Therapy 41
5.2.3 Market Size 41
5.3 Australia 43
5.3.1 Treatment Usage Patterns 43
5.3.2 Annual Cost of Therapy 43
5.3.3 Market Size 43
5.4 China 45
5.4.1 Treatment Usage Patterns 45
5.4.2 Annual Cost of Therapy 45
5.4.3 Market Size 45
5.5 Japan 47
5.5.1 Treatment Usage Patterns 47
5.5.2 Annual Cost of Therapy 47
5.5.3 Market Size 47
5.6 Drivers and Barriers 49
5.6.1 Drivers 49
5.6.2 Barriers 50
6 Ophthalmology Therapeutics Market in Asia-Pacific – Deals and Strategic Consolidations (Global) 51
6.1 Deals Analysis 51
6.2 Major Co-Development Deals 52
6.2.1 NicOx Signs Research Agreement with Pfizer 53
6.2.2 Acucela Enters into Co-Development Agreement with Otsuka Pharma for Rebamipide 53
6.2.3 Akorn Enters into Agreement with Azad Pharma 53
6.3 Major Licensing Deals 54
6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 55
6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 55
6.3.3 Asterand Enters into Licensing Agreement with Allergan 55
7 Ophthalmology Therapeutics Market in Asia-Pacific – Appendix 56
7.1 All Pipeline Drugs by Phase 56
7.1.1 Discovery 56
7.1.2 Preclinical 56
7.1.3 IND/CTA-filed 58
7.1.4 Phase I 58
7.1.5 Phase II 59
7.1.6 Phase III 60
7.1.7 Pre-registration 60
7.1.8 Undisclosed 61
7.2 Market Forecasts to 2019 61
7.2.1 APAC 61
7.2.2 Australia 62
7.2.3 China 62
7.2.4 India 63
7.2.5 Japan 64
7.3 Market Definitions 64
7.4 Abbreviations 64
7.5 Sources 66
7.6 Research Methodology 67
7.6.1 Coverage 67
7.6.2 Secondary Research 68
7.6.3 Primary Research 68
7.6.4 Therapeutic Landscape 69
7.6.5 Geographical Landscape 71
7.6.6 Pipeline Analysis 71
7.7 Expert Panel Validation 71
7.8 Contact Us 71
7.9 Disclaimer 72